AZTherapies Overview

  • Founded
  • 2011
Founded
  • Status
  • Private
  • Employees
  • 32
Employees
  • Latest Deal Type
  • Series C1
  • Latest Deal Amount
  • $33.6M
Latest Deal Amount
  • Investors
  • 14

AZTherapies General Information

Description

Developer of pharmaceutical drugs designed to provide treatment for multiple neurodegenerations and neuroinflammation-related CNS diseases. The company's products include a novel multi-action combination drug regimen that is used to modify disease progression by slowing down or halting Alzheimer's disease early in its development, enabling healthcare providers to cure Alzheimer's patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • 200 Clarendon Street
  • 17th Floor
  • Boston, MA 02116
  • United States
+1 (617) 000-0000

AZTherapies Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

AZTherapies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series C1) 29-Sep-2020 $33.6M 00000 00000 Completed Clinical Trials - Phase 3
6. Debt - PPP 19-May-2020 000.00 Completed Clinical Trials - Phase 3
5. Later Stage VC (Series C) 31-Jan-2020 000.00 000.00 00000 Completed Clinical Trials - Phase 3
4. Later Stage VC (Series B) 16-Oct-2018 000.00 000.00 00000 Completed Clinical Trials - Phase 3
3. Later Stage VC (Series A) 0000 000.00 00000 Completed Clinical Trials - Phase 3
2. Later Stage VC (Series A) 06-Feb-2017 $16.4M $26.4M 00000 Completed Clinical Trials - Phase 3
1. Early Stage VC 06-Jan-2015 $10M $10M Completed Clinical Trials - Phase 3
To view AZTherapies’s complete valuation and funding history, request access »

AZTherapies Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C1 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
Series C 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series B 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
Series A-2 0,000,000 00.000000 00.0 00.0 00 00.0 0.000
Series A-1 2,084,052 $0.000100 $3.33 $3.33 1x $3.33 3.8%
Series A 4,212,559 $0.000100 $4 $4 1x $4 7.69%
To view AZTherapies’s complete cap table history, request access »

AZTherapies Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of pharmaceutical drugs designed to provide treatment for multiple neurodegenerations and neuroinflammation-re
Drug Discovery
Boston, MA
32 As of 2021
00000
0000 0000-00-00
00000000000 00000

0000

dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui
0000000000000
San Diego, CA
00 As of 0000
00.000
0.00 0000-00-00
0000000000 0

0000000

tation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehender
0000000000000
Cambridge, MA
0 As of 0000
0000
000 0000-00-00
00000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AZTherapies Competitors (39)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ALSP Venture Capital-Backed San Diego, CA 00 00.000 0000000000 0
0000000 0000000000 Venture Capital-Backed Cambridge, MA 0 0000 00000000000 0000
000 000000 Venture Capital-Backed Boston, MA 0 000.00 0000000000 0 000.00
0000000 Venture Capital-Backed San Carlos, CA 00 000.00 00000 00000 000.00
0000000 Angel-Backed Weston, FL 00 0000 0000000000 0000
You’re viewing 5 of 39 competitors. Get the full list »

AZTherapies Executive Team (9)

Name Title Board Seat Contact Info
Marc de Garidel Chief Executive Officer & Board Member
Karen Reeves MD President & Chief Medical Officer
Brian Bartlett Chief Financial & Accounting Officer
David Elmaleh Ph.D Scientific Founder, Chairman & Chief Scientific Officer
David King Advisor
You’re viewing 5 of 9 executive team members. Get the full list »

AZTherapies Board Members (11)

Name Representing Role Since
David Elmaleh Ph.D AZTherapies Scientific Founder, Chairman & Chief Scientific Officer 000 0000
David Taft Self Board Member 000 0000
George Behrakis AZTherapies Board Member 000 0000
Gillian Sandler Self Board Member 000 0000
Keith Greenfield AZTherapies Board Member & Senior Advisor to the CEO 000 0000
You’re viewing 5 of 11 board members. Get the full list »

AZTherapies Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AZTherapies Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Catalytic Impact Foundation Not-For-Profit Venture Capital Minority 000 0000 000000 0
DEFTA Partners Venture Capital Minority 000 0000 000000 0
Duopharma Biotech Berhad Corporation Minority 000 0000 000000 0
Axiom Associates Venture Capital Minority 000 0000 000000 0
Cosine (NYC biotech investors) Other Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »

AZTherapies Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 000000000000 24-Oct-2019 000000000000000000 Biotechnology 00000 0000000 00.0
To view AZTherapies’s complete acquisitions history, request access »